Alternatively, the DREAMseq and SECOMBIT trials comparing the use of combination ICB (nivolumab plus ipilimumab) and BRAF/MEK inhibitors in sequence both showed superior OS outcomes with the initial use of immunotherapy compared to the converse sequence suggesting that this approach (rather than triple therapy) should be preferred for most patients with metastatic BRAF‐mutant melanoma [13, 35]. The gene discussed is MAP2K7; the disease is melanoma.